[HTML][HTML] Bullous pemphigoid

D Miyamoto, CG Santi, V Aoki… - Anais brasileiros de …, 2019 - SciELO Brasil
Bullous pemphigoid is the most frequent autoimmune bullous disease and mainly affects
elderly individuals. Increase in incidence rates in the past decades has been attributed to …

Pemphigoid diseases

E Schmidt, D Zillikens - The Lancet, 2013 - thelancet.com
Pemphigoid diseases are a group of well defined autoimmune disorders that are
characterised by autoantibodies against structural proteins of the dermal–epidermal junction …

Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)

L Borradori, N Van Beek, C Feliciani… - Journal of the …, 2022 - Wiley Online Library
Background Bullous pemphigoid (BP) is the most common autoimmune subepidermal
blistering disease of the skin and mucous membranes. This disease typically affects the …

Diagnosis and management of pemphigus: Recommendations of an international panel of experts

DF Murrell, S Peña, P Joly, B Marinovic… - Journal of the American …, 2020 - Elsevier
Background Several European countries recently developed international diagnostic and
management guidelines for pemphigus, which have been instrumental in the …

Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology

C Feliciani, P Joly, MF Jonkman… - British journal of …, 2015 - academic.oup.com
Bullous pemphigoid is the most common autoimmune subepidermal blistering disease of
the skin and mucous membranes. This disease typically affects the elderly and presents with …

Bullous pemphigoid: a review of its diagnosis, associations and treatment

P Bernard, F Antonicelli - American journal of clinical dermatology, 2017 - Springer
Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease
in Western countries, and typically affects the elderly. BP is immunologically characterized …

[HTML][HTML] Autoantibody profile differentiates between inflammatory and noninflammatory bullous pemphigoid

K Izumi, W Nishie, Y Mai, M Wada, K Natsuga… - Journal of investigative …, 2016 - Elsevier
Bullous pemphigoid (BP) is a major autoimmune blistering skin disorder, in which a majority
of the autoantibodies (autoAbs) target the juxtamembranous extracellular noncollagenous …

Association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors in patients with diabetes: estimating the risk of the new agents and characterizing the patients

K Kridin, R Bergman - JAMA dermatology, 2018 - jamanetwork.com
Importance The association of bullous pemphigoid (BP) with the use of dipeptidyl-peptidase
4 (DPP-4) inhibitors among patients with diabetes has recently emerged. The risk of …

[HTML][HTML] Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial

HC Williams, F Wojnarowska, G Kirtschig, J Mason… - The Lancet, 2017 - thelancet.com
Background Bullous pemphigoid is a blistering skin disorder with increased mortality. We
tested whether a strategy of starting treatment with doxycycline gives acceptable short-term …

[HTML][HTML] Efficacy and safety of dupilumab in moderate-to-severe bullous pemphigoid

Y Zhang, Q Xu, L Chen, J Chen, J Zhang… - Frontiers in …, 2021 - frontiersin.org
Background Bullous pemphigoid (BP) is an autoimmune blistering disorder that
predominantly affects the elderly. As the main treatment for BP, systemic corticosteroids are …